Rev Clin Esp (Barc). 2026 Jan 9:502455. doi: 10.1016/j.rceng.2026.502455. Online ahead of print.
ABSTRACT
INTRODUCTION: GLP-1 receptor agonists, such as semaglutide, have demonstrated cardiovascular benefits in trials such as SELECT and SOUL. This study assesses the proportion of post-myocardial infarction patients who meet eligibility criteria to benefit from semaglutide.
METHODS: A retrospective, single-centre observational study was conducted including 100 consecutive patients following myocardial infarction. Clinical, demographic, and laboratory data were analysed. Eligibility was assessed using the criteria from the SELECT trial (body mass index ≥27 kg/m², no diabetes, established atherosclerotic disease) and the SOUL trial (type 2 diabetes mellitus and atherosclerotic cardiovascular disease).
RESULTS: SELECT criteria were met by 42 patients, SOUL criteria by 34, and both by 76. This combined group was characterised by older age, greater comorbidity burden (hypertension, dyslipidaemia, type 2 diabetes mellitus), higher body mass index, and a more atherogenic lipid profile.
DISCUSSION: The high proportion of eligible patients suggests that these trials truly represent real-world clinical practice. The SELECT + SOUL group exhibited features consistent with metabolic syndrome, potentially explaining their elevated cardiovascular risk and the likely benefit from semaglutide.
CONCLUSIONS: Semaglutide shows high potential for prescription in specialties managing patients with cardiovascular events, identifying a target group with characteristics typical of metabolic syndrome.
PMID:41520703 | DOI:10.1016/j.rceng.2026.502455